HydRegen Closes $8M (£6M) Series A for Industrial Biocatalysis

HydRegen has raised $8 million (£6 million) in a Series A round to move biocatalysis from the lab into industrial chemical manufacturing, according to The National Law Review.

The round marks the company's first major institutional financing since it began developing enzyme-based catalysts as an alternative to metal-dependent industrial processes. The company, an Oxford University spinout, builds biocatalytic technology that uses hydrogen-driven enzymes to carry out chemical reactions at scale.

What does this change for chemical manufacturers?

For producers, the pitch is straightforward. Biocatalysis replaces precious-metal catalysts — the kind exposed to price swings and supply-chain risk — with enzymes that run under milder conditions. That translates into lower energy demand and less reliance on mined inputs, two cost lines that have squeezed chemical margins in recent years.

The $8 million gives HydRegen the runway to prove its technology works outside pilot conditions. Scaling enzymes to industrial volumes has historically been the hard part, and that's exactly what this round is meant to fund.

Why the money matters now

Six million pounds won't build a chemical plant, but it will fund the engineering work needed to convince bigger partners that biocatalysis can handle real production loads. For a company at Series A stage, the check size signals institutional confidence that enzyme catalysis is ready for its industrial debut rather than another decade in the lab.

Investor appetite for green-chemistry platforms has grown as manufacturers face pressure to cut energy intensity and decarbonize process chemistry. HydRegen sits squarely in that lane: its technology targets reactions that conventionally require high heat, high pressure, or rare metals.

The National Law Review's report did not name the round's lead investor or disclose a valuation. It also did not specify a timeline for deployment of the new capital.

The road ahead

The next milestone for HydRegen is demonstrating its biocatalysts at industrially relevant scale. If the company clears that hurdle, chemical manufacturers gain a credible route to cutting both energy costs and metal-catalyst exposure — and HydRegen converts a £6 million raise into a foothold in a market actively hunting cleaner process technology.